Sanovas, a US-based life science technology company, has submitted an application to the US Food and Drug Administration (FDA) seeking approval to use its miniaturised interventional catheter for treating patients with chronic pulmonary diseases and lung cancer.
The Vas Zeppelin Smart Catheter, which the company claims is the smallest interventional catheters commercially available, is designed for operating on a breathing lung and minimising the procedural risks associated with pulmonary intervention, including damage to the treatment site and/or post-operative complications.
Sanovas CEO Larry Gerrans said: "With one in seven Americans suffering from chronic pulmonary disease and with lung cancer killing more people than breast, prostate and colon cancers combined, new technologies aimed at the earliest stages of lung disease are desperately needed."
The miniaturised catheter, which features a portfolio of integrated tools and sensors, is intended to synergise access, 3D imaging, physiologic metrics, on-board diagnostics and related therapy.
The solution is expected to help remove obstructions and deliver drug and immune therapies to the smallest and most remote passageways in the human body.
The launch of Vas Zeppelin will also serve as the cornerstone to the Sanovas’s arsenal of therapy enabling solutions, according to the company.
Sanovas’s intellectual property portfolio, which includes two patents issued and more than 40 patents pending, will offer broad protection to the new miniaturised technology, which is considered as the first intelligent and integrated approach.
The company will actively file for clearance of its follow-on technologies in the coming months.
